How to Get Trulicity (Dulaglutide) in Virginia

What Is Trulicity and Why Is It Prescribed?

Dulaglutide is a once-weekly GLP-1 receptor agonist that the FDA approved in September 2014 for glycemic control in adults with type 2 diabetes. It works by mimicking the incretin hormone GLP-1, which stimulates glucose-dependent insulin secretion and suppresses glucagon release after meals.

The drug is sold exclusively under the brand name Trulicity in prefilled, single-dose pens at four dosage strengths: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg. Eli Lilly manufactures all dosage forms. The standard starting dose is 0.75 mg injected subcutaneously once per week, with titration to 1.5 mg after four weeks if additional glycemic control is needed [1]. Doses of 3.0 mg and 4.5 mg became available after a 2020 label expansion and are reserved for patients who need more aggressive A1C reduction beyond what 1.5 mg provides [2].

Beyond blood sugar management, dulaglutide carries a cardiovascular indication. The REWIND trial (N=9,901) demonstrated a 12% relative risk reduction in major adverse cardiovascular events (MACE) over a median follow-up of 5.4 years among adults with type 2 diabetes who had cardiovascular risk factors or established disease [3]. That result led the FDA to add a cardiovascular risk-reduction statement to the Trulicity label. The American Diabetes Association (ADA) 2024 Standards of Care now recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred second-line agents for patients with type 2 diabetes and established atherosclerotic cardiovascular disease [4].

Virginia Telehealth Rules for Trulicity Prescriptions

Virginia law allows licensed prescribers to evaluate patients and write prescriptions through real-time audio-video telehealth encounters. No in-person visit is required before prescribing dulaglutide, provided the clinician establishes an adequate patient-provider relationship during the virtual appointment.

The Virginia Board of Medicine requires that telehealth providers hold an active Virginia medical license or a valid license through an interstate compact. Nurse practitioners in Virginia have full practice authority after completing a supervised practice period, meaning they can independently prescribe Trulicity without physician co-signature once that requirement is met [5]. Physician assistants may also prescribe under their collaborative agreement with a supervising physician.

Several national telehealth platforms serve Virginia patients seeking GLP-1 prescriptions. A typical telehealth workflow looks like this: a patient completes an intake form, uploads recent lab results (fasting glucose, HbA1c, basic metabolic panel), participates in a synchronous video visit, and receives an electronic prescription sent directly to their preferred pharmacy. Turnaround from initial consultation to pharmacy submission is often 24 to 72 hours, though insurance prior authorization can extend the timeline by 5 to 15 business days.

Virginia does not impose any state-specific telehealth restrictions on GLP-1 receptor agonists beyond the standard prescribing regulations that apply to all prescription medications. This makes the state one of the more accessible for patients pursuing remote diabetes care.

Required Labs Before Starting Dulaglutide

Prescribers will not write a Trulicity prescription without baseline laboratory values. These labs confirm the type 2 diabetes diagnosis, rule out contraindications, and establish monitoring benchmarks.

The minimum panel includes HbA1c (to confirm glycemic status and set a reduction target), fasting plasma glucose, a comprehensive metabolic panel covering renal function (eGFR, BUN, creatinine) and hepatic markers (ALT, AST), and a lipid panel. The ADA recommends an HbA1c target of <7% for most adults, though individualized targets between 6.5% and 8% may apply depending on age and comorbidity burden [4].

Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Thyroid function tests (TSH, free T4) are often ordered alongside the baseline panel, though they are not universally mandated. A serum lipase or amylase level may be checked if the patient reports any history of pancreatitis, since GLP-1 receptor agonists carry a labeled precaution for acute pancreatitis risk [1].

Most Virginia labs, including Quest Diagnostics and Labcorp locations throughout the state, can process these panels. Results are typically available within 1 to 3 business days. Telehealth providers usually accept uploaded lab work completed within the prior 90 days.

Insurance Coverage and Prior Authorization in Virginia

The majority of commercial plans sold in Virginia cover Trulicity on their formularies, though nearly all require prior authorization (PA) before approving the claim. Virginia Medicaid covers dulaglutide for type 2 diabetes with PA as well.

A successful PA submission typically requires documentation of the patient's HbA1c level (most payers want to see HbA1c ≥7% despite first-line therapy), evidence that metformin was tried for at least 90 days or is contraindicated, the prescriber's clinical rationale, and a copy of recent lab results. The insurer's pharmacy benefit manager reviews the request and returns a decision within 72 hours for standard requests or 24 hours for urgent/expedited reviews under Virginia insurance regulations.

Trulicity's wholesale acquisition cost runs approximately $930 to $1,000 per month without insurance. Eli Lilly offers a savings card that can reduce out-of-pocket costs to as little as $25 per month for commercially insured patients, though this benefit does not apply to government-funded plans like Medicaid, Medicare, or Tricare [6]. Patients denied coverage can file an appeal. A 2023 analysis published in Diabetes Care found that GLP-1 receptor agonist PA denial rates ranged from 15% to 30% across commercial payers, with the most common denial reason being insufficient documentation of first-line therapy failure [7].

For Virginia Medicaid enrollees specifically, the Department of Medical Assistance Services (DMAS) publishes preferred drug lists that may favor certain GLP-1 receptor agonists over others. Checking the current DMAS formulary before submitting a PA can save time.

Pharmacy Options for Filling Trulicity in Virginia

Virginia residents can fill a Trulicity prescription at any licensed retail pharmacy, including CVS, Walgreens, Walmart, and independent pharmacies across the Commonwealth. The prescription is transmitted electronically from the prescriber.

Specialty pharmacies are another option, particularly for patients whose insurance routes GLP-1 prescriptions through a specialty benefit rather than the standard pharmacy benefit. Express Scripts, Optum Specialty, and Accredo all ship to Virginia addresses, typically with cold-chain packaging to maintain the required 36°F to 46°F storage range.

Virginia also licenses 503A compounding pharmacies that may prepare dulaglutide formulations under certain conditions. A 503A pharmacy compounds patient-specific prescriptions based on an individual prescription order from a licensed prescriber [8]. These pharmacies must comply with both Virginia Board of Pharmacy regulations and federal guidelines under Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded GLP-1 formulations may become relevant when branded supply faces shortages, though patients should confirm with their prescriber that any compounded product meets equivalent quality standards.

Shipping timelines within Virginia are typically 1 to 3 business days for specialty and mail-order pharmacies. Retail fill at a local pharmacy can happen the same day if the drug is in stock and PA has already been approved.

Dulaglutide Dosing, Titration, and What to Expect

The standard titration schedule starts at 0.75 mg weekly for at least four weeks, then increases to 1.5 mg weekly. If HbA1c remains above target after at least four weeks on 1.5 mg, the dose can be increased to 3.0 mg, and subsequently to the maximum dose of 4.5 mg weekly [1].

Gastrointestinal side effects are the most common reason patients contact their provider during the first weeks of therapy. Nausea affected 12.4% of patients on dulaglutide 0.75 mg and 21.1% on 1.5 mg in the AWARD-1 trial, compared to 6.7% on placebo [9]. Diarrhea and vomiting also occur, though these symptoms are usually transient and improve within the first two to four weeks. Eating smaller meals, avoiding high-fat foods, and staying hydrated can reduce nausea severity.

Injection technique matters. Trulicity pens are designed with a hidden needle and a one-click mechanism. Patients inject into the abdomen, thigh, or upper arm, rotating injection sites weekly to avoid lipodystrophy. The pen does not require reconstitution or manual needle attachment, which simplifies the process compared to some other injectable diabetes medications.

Patients typically see measurable A1C reductions within 12 weeks. In the AWARD-11 trial, dulaglutide 4.5 mg reduced HbA1c by 1.87% from baseline at 36 weeks, compared to 1.54% for the 1.5 mg dose [10]. Weight loss is a secondary benefit: AWARD-11 participants on 4.5 mg lost an average of 4.6 kg (approximately 10.1 lbs) over the same period.

Who Can Prescribe Trulicity in Virginia

Three categories of clinicians hold prescriptive authority for dulaglutide in Virginia: physicians (MD and DO), nurse practitioners, and physician assistants.

Physicians have unrestricted prescriptive authority. Any Virginia-licensed MD or DO can prescribe Trulicity regardless of specialty, though endocrinologists, internists, and family medicine physicians write the majority of GLP-1 prescriptions. Virginia does not require specialist referral before initiating a GLP-1 receptor agonist.

Nurse practitioners in Virginia gained full practice authority under legislation effective July 1, 2022. After completing a minimum practice period (typically two years or 3,600 hours under a practice agreement with a physician), NPs can prescribe Schedule II through VI medications independently. Trulicity is not a controlled substance, so any NP with prescriptive authority can prescribe it.

Physician assistants prescribe under a collaborative practice agreement with a supervising physician. The agreement must specify the scope of prescriptive authority. Most PA collaborative agreements in primary care and endocrinology settings include GLP-1 receptor agonists.

Telehealth prescribers must hold a Virginia license or practice under an applicable interstate compact. Out-of-state providers without Virginia licensure cannot legally prescribe to Virginia residents.

Transferring an Existing Trulicity Prescription to Virginia

Patients relocating to Virginia from another state can transfer an active Trulicity prescription. The process involves contacting the new Virginia pharmacy (retail or mail-order) and providing the current prescription details. The receiving pharmacy then contacts the originating pharmacy to verify and transfer the prescription.

Virginia pharmacies accept prescription transfers for non-controlled medications like dulaglutide without restriction. The original prescription must have remaining refills. If the prescription has expired or has no refills left, a new prescription from a Virginia-licensed provider is required.

For patients using a telehealth platform, the simplest route is to schedule a follow-up visit with a provider licensed in Virginia. Most platforms can access prior visit records and lab results, which streamlines the transition. Patients should bring recent labs (within 90 days) and a record of their current dose to the appointment.

Insurance changes during relocation can complicate pharmacy transfers. A new PA submission under the new plan is often required, even if the previous insurer had already approved Trulicity. Plan ahead by initiating the PA process as soon as the new insurance becomes active, ideally while still holding a supply of medication from the prior fill.

Cardiovascular and Renal Evidence Supporting Dulaglutide Use

The REWIND trial remains the landmark cardiovascular outcomes study for dulaglutide. Published in The Lancet in 2019, REWIND enrolled 9,901 adults with type 2 diabetes across 24 countries. Participants had either established cardiovascular disease or cardiovascular risk factors. Over a median 5.4-year follow-up, dulaglutide 1.5 mg reduced the composite MACE endpoint (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) by 12% compared to placebo (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) [3].

A secondary analysis of REWIND published in The Lancet Diabetes & Endocrinology showed that dulaglutide reduced the composite renal outcome (new macroalbuminuria, sustained decline in eGFR of ≥30%, or chronic renal replacement therapy) by 15% (HR 0.85, 95% CI 0.77 to 0.93, P=0.0004) [11]. Dr. Hertzel Gerstein, the REWIND principal investigator, stated: "Dulaglutide reduced the development of new macroalbuminuria by 23%, which has significant implications for the long-term renal outcomes of people with type 2 diabetes."

The ADA's 2024 Standards of Care cite REWIND among the evidence base for recommending GLP-1 receptor agonists in patients with type 2 diabetes who have or are at high risk for atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [4]. Virginia clinicians evaluating whether to prescribe Trulicity should weigh these cardiovascular and renal benefits alongside glycemic efficacy, particularly for patients who carry multiple cardiometabolic risk factors.

Monitoring and Follow-Up After Starting Trulicity

Once a patient in Virginia begins dulaglutide therapy, follow-up visits (in person or via telehealth) are typically scheduled at 4 weeks, 12 weeks, and then every 3 to 6 months. The 4-week check assesses tolerability and determines readiness for dose titration. The 12-week visit is the first meaningful HbA1c reassessment, since A1C reflects a roughly 90-day average of blood glucose.

Ongoing monitoring includes HbA1c every 3 to 6 months until stable, annual lipid panels, periodic renal function checks (at least annually or more often if baseline eGFR is <60 mL/min/1.73 m²), and symptom review for gastrointestinal side effects, injection-site reactions, and signs of pancreatitis (persistent severe abdominal pain radiating to the back) [1]. Patients should be instructed to discontinue Trulicity and seek immediate medical attention if pancreatitis symptoms develop.

Weight and blood pressure should be tracked at each visit. The ADA recommends a blood pressure target of <130/80 mmHg for most adults with diabetes [4]. Dulaglutide's modest weight-loss effect (2 to 5 kg on average across AWARD trials) may contribute to improved blood pressure in overweight patients, though it should not be relied upon as a primary antihypertensive strategy.

Virginia telehealth platforms can handle most follow-up encounters. Lab orders can be placed electronically and completed at local draw stations, with results reviewed during the virtual visit. Prescription renewals are issued electronically, keeping the refill cycle uninterrupted.